S
ince its introduction in breast imaging, the use of magnetic resonance imaging (MRI) technology has become a source of contentiousness between its ardent supporters and its fierce critics. No sooner had consensus been reached that MRI screening for breast can cer should be restricted to high-risk women than a new controversy flared over its preoperative use in early-stage breast cancer patients.
Fueling the debate is a recent fl urry of reports suggesting that MRI use increases mastectomy rates, prolongs the time from diagnosis to treatment, and may increase the rate of overdiagnosis (detection of clinically insignifi cant cancers). Staunch advocates of preoperative MRIs, however, argue that in their hands it reduces reexcision surgeries and therefore reduces costs.
Most recently, in a review of more than two dozen recent studies, Nehmat Houssami, Ph.D., of Sydney Medical School, University of Sydney, Australia, and Daniel Hayes, M.D. , of the University of Michigan Comprehensive Cancer Center, Ann Arbor, conclude that little evidence exists to support the routine use of MRI in the care of newly diagnosed breast cancer patients.
When the investigators pooled data from 12 primary studies on changes in surgical management based on MRI detection, they found that 11.3% of patients had more extensive surgery than initially planned and that 8.1% of women originally thought eligible for breast-conserving surgery converted to mastectomy because of MRI fi ndings of additional suspicious lesions. The review, published in CA: A Cancer Journal for Clinicians , argues that MRI could have a potentially harmful effect.
"What really breaks my heart is seeing an increased rate of mastectomies after 40 years of battling over doing breast conservation," said Hayes. "I lived through the mastectomy versus breast conservation wars . . . but because of randomized trials, and surgeons willing to challenge their [own] dogma, and because we chose appropriate endpoints, we convinced ourselves that breast conservation was every bit as good as a mastectomy. And now we are reversing those great successes."
Identical Outcomes
The authors say that preoperative MRI has been based on an assumption that MRI's proven sensitivity at detecting suspicious lesions would improve surgical planning and reduce the need for reexcision surgery, as well as potentially reduce recurrence in the treated breast. However, studies challenge that assumption, they say. However, Alan Hollingsworth, M.D., a breast surgeon at Mercy Health Center in Oklahoma City, Okla., and a critic of the COMICE trial, is quick to point out that women in that trial were already planning on having breast conservation; therefore, the trial could not address how many patients who had been planning on having a mastectomy converted to breast conservation after having a clean MRI scan.
will be led by principal investigator Larry Kessler, Sc.D., professor of public health at the University of Washington, Seattle, and former U.S. Food and Drug Administration staffer. Plans call for it to establish a network of health care delivery systems to include the University of Washington, Group Health, the Veterans Administration, several private health insurance companies, the Health Care Authority of the State of Washington, Medicaid, and the Seattle Cancer Care Alliance. The funding will not include traditional measures of sensitivity and specifi city. Instead, the investigators will test the hypothesis that the likelihood of receiving surgery, chemotherapy, or radiation therapy will not differ among patients who have MRI, PET -CT, both, or neither technology within 6 months of a diagnosis of breast cancer. "What we are trying to do is look at the variability across the community and exploit the variability over time, place, and provider to see if treatment and possibly morbidity and local recurrence are different because of the use and existence of these technologies," Kessler said.
He acknowledges that looking at endpoints such as mortality or recurrence will be impossible in the short, 2-year span of the grant, but once the infrastructure is in place, the group plans to collect prospective data to look at the use of imaging technologies in staging breast cancers and at outcomes. Gathering those data will take many years. In the interim, oncologists such as Silverstein say they will continue to use MRI despite the absence of clinical trials showing its effectiveness.
"If you want to base it on science, [Monica Morrow] is probably closer to correct than the rest of us," said Silverstein. "We like MRI. We think it's valuable to us, but if you get me into the corner and say, 'Prove it to me, ' I can't prove it to you." "I use MRI with every single patient with breast cancer," Silverstein said. "I want to look at every single bit of information that's available, discuss it with the patient, and then fi gure out the best thing for that patient. That's the way I work."
Silverstein also pointed to an emerging treatment that he said would incorporate MRIs. Single-dose intraoperative radiotherapy is being compared to conventional postoperative radiotherapy in the TARGIT trial, an international randomized controlled clinical trial for women with early-stage invasive breast cancer who are scheduled for breast-conserving surgery. The study is enrolling 2,400 women older than 40 years who have been diagnosed with a single invasive breast cancer of 3 cm. or less. Intraoperative radiotherapy differs from partial breast irradiation in that it consists of one 30-minute dose during surgery, as opposed to a 5-day dose. The Norris Cancer Center is one of the trial sites. "One-shot radiation therapy is coming to this country, and it's going to be a big thing," said Silverstein. "We are starting a trial with it, and one of the things we require is an MRI to make sure there isn't a second lesion somewhere else that would make this trial fail."
Comparing Effectiveness
More data on preoperative MRIs could come from comparative effectiveness research, an evaluation of the effect of different diagnostic and treatment options that looks at "real world" data, not just clinical trials in controlled, randomized settings. One of the fi rst such studies funded through the federal government's economic stimulus act will compare the effectiveness of mammography, MRI, ultrasound, PET -CT (positron emission tomography -computed tomography), and tumor biomarkers for establishing extent of disease among newly diagnosed stage I -III breast cancer patients. The $4 million study, known as ADVICE, Silverstein recently led a diverse, interdisciplinary group of breast cancer physicians who met in June 2009 to discuss their experiences with image-detected breast cancer and draft a consensus report on the use of various imaging methods. That report, published in the October issue of the Journal of the American College of Surgeons , took a positive view of the role of MRI in treatment decision making. At the same time, the authors acknowledge that no evidence yet exists from randomized trials that MRI will reduce the risk of local recurrence or improve survival. 
